Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The Rhythms of the Street: Shipping's Tune in the Economy's Symphony - 2Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- 3VPN Administrations for Online Protection
- 4In wrangling dark matter, some scientists find inspiration in the Torah, Krishna and Christ
- 5The Specialty of Cleaning up: Change Your Space and Brain
- Germany unveils rescue plan for struggling chemical sector
- The Way to Monetary Health: Individual budget Change
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- The cave was pitch black – so to create this magical underwater shot, the photographer had to use all his camera expertise...
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Rescuers attempt to dig free whale stranded on Germany's Baltic coast
- Anthony Joshua's driver charged over Nigeria crash that killed two
- 'Unreal' solar eclipse: Artemis 2 crew just saw one of the rarest sights in spaceflight history
- ‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
